



Radius Health, Inc.  
Investor Relations Department  
950 Winter St, North Building 1st Floor  
North Building 1st Floor  
Waltham, MA 02451  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

#### NASDAQ: RDUS

|               |                            |
|---------------|----------------------------|
| Last Trade:   | 42.22                      |
| Trade Time:   | 4:00 PM ET<br>Jul 21, 2017 |
| Change:       | -0.12  (-0.283%)           |
| Day Range     | 39.25 - 43.00              |
| 52-Week Range | 31.58 - 59.88              |
| Volume        | 2,631,835                  |

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Radius' lead product, TYMLOS (abaloparatide) Injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Radius' Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe. The Radius clinical ... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

*Jul 21, 2017*  
[Radius Health Announces that the Committee for Medicinal Products for Human Use \(CHMP\) Has Issued a Second Day-180 List of Outstanding Issues in its Regulatory Review of Eladynos™ \(Abaloparatide-SC\), a Bone Building Agent for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture](#)

*Jul 18, 2017*  
[Radius Health Announces New Employment Inducement Grant](#)

*Jul 17, 2017*  
[Radius Health Appoints Jesper Høiland as President and Chief Executive Officer To Lead The Next Stage Of Growth and Value Creation As A Fully Integrated Commercial Biotech Company](#)

*Jul 13, 2017*  
[Radius Health Announces License and Development Agreement for Abaloparatide-SC with Teijin Limited in Japan](#)

*Jul 7, 2017*  
[Radius Health to Announce Second Quarter 2017 Financial Results, Host Conference Call and Live Webcast on August 3, 2017](#)

## Upcoming Events [\[ View all \]](#)

*Aug 3, 2017 4:30 PM ET*  
[Radius Health Second Quarter 2017 Financial Results](#)

## Financials [\[ View all \]](#)

*Feb 24, 2017*  
[Annual Report \(10-K\)](#)

*Apr 21, 2017*  
[Proxy Statement \(DEF 14A\)](#)

*May 2, 2017*  
[Quarterly Report \(10-Q\)](#)

*Nov 3, 2016*  
[Quarterly Report \(10-Q\)](#)

*Aug 4, 2016*  
[Quarterly Report \(10-Q\)](#)